UnitedHealth Group Incorporated research snapshot
UNH AI stock analysis currently reads UnitedHealth Group as a dominant U.S. managed care and health services platform whose scale, Optum assets, pharmacy services, provider relationships, and data depth remain valuable, but whose 2025 earnings reset, Medicare Advantage pressure, DOJ and regulatory scrutiny, and medical cost trend keep the setup scenario-based. At the July 8, 2026 data cutoff, UNH traded near $427.78 with a verified market cap near $388.49 billion, Q1 2026 revenue of $111.7 billion, and management guidance for adjusted 2026 EPS greater than $18.25. This page is for research and education only, not investment advice.
Current price
$427.78
Market cap
$388.49 billion verified market cap
AI score
64 / 100
Rating
Scaled health care platform with a recovering earnings path and high policy sensitivity
Trend status
Technically constructive above major moving averages, fundamentally still proving the post-2025 recovery
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | UnitedHealth earns through UnitedHealthcare insurance risk pooling and Optum health services, care delivery, analytics, and pharmacy benefits, giving it unmatched health care scale. | High |
| Moat | The moat comes from scale, provider networks, claims data, Optum integration, pharmacy purchasing depth, employer and government relationships, and regulated-market experience. | Medium-high |
| Management | Stephen Hemsley returned as CEO in 2025 after a difficult earnings reset. The key test is whether management can restore credibility, cost control, compliance, and Optum Health discipline. | Medium |
| Financial trend | FY2025 revenue grew to $447.567 billion, but net earnings fell from prior normalized levels. Q1 2026 improved with $111.7 billion revenue, $9.0 billion operating earnings, and $7.23 adjusted EPS. | High |
| Valuation | At $427.78, verified math shows about 32.24x TTM EPS, 3.69x book value, 0.86x sales, and a 2.07% dividend yield on the inputs used here. | Medium-high |
| Technical trend | UNH trades above Barchart 50-day and 200-day moving averages, with RSI in the low 60s and resistance near the recent $428 to $434 area. | Medium-high |
| Risk level | Risk remains elevated for a mega-cap health insurer because medical cost trend, CMS rates, DOJ scrutiny, Medicare Advantage membership, PBM pressure, and public trust can reset earnings quickly. | High |
| AI confidence | Descriptive confidence is high because filings, releases, and market data are rich. Return confidence is lower because policy and medical-cost assumptions dominate the forecast. | High data confidence |
| Investment certainty | UNH is a recovery execution watch rather than a low-uncertainty compounder at the current price. | Medium-low |
UNH AI stock forecast
The UNH AI stock forecast should be read as scenario math, not a promised price target. Using the July 8, 2026 research cutoff, a $427.78 price reference, TTM EPS of $13.27, and a three-year model, the tested range spans roughly $150 in a bearish case, $285 in a base case, and $447 in a bullish case before dividends. The range is wide because normalized earnings depend on medical cost control, Medicare Advantage repricing, Optum Health execution, compliance outcomes, and whether investors restore a premium multiple.
$430 to $470 before dividends
More likely if Q2 and Q3 results confirm the Q1 2026 recovery, adjusted EPS grows from the greater than $18.25 guide, medical care ratio stays controlled, Medicare Advantage pricing improves, and legal headlines do not impair the franchise.
$270 to $310 before dividends
More likely if earnings recover only gradually from the 2025 reset, investors value UNH closer to a high-teens multiple on depressed trailing EPS, and Optum Health margin improvement remains uneven.
$140 to $170 before dividends
More likely if medical utilization stays elevated, Medicare Advantage membership and rates disappoint, DOJ or CMS issues create larger costs, PBM pressure intensifies, or investors value UNH on stressed earnings.
UNH AI technical analysis
UNH AI technical analysis is constructive as of the July 8, 2026 data cutoff. Barchart showed UNH near $428.19 with a 50-day moving average near $393.22 to $394.66, a 200-day moving average near $338.13 to $338.59, 14-day RSI near 62.84, and 50-day average volume around 6.8 million shares. Investing.com also described the daily indicator set as Strong Buy, though its moving-average values differed by data vendor.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $427.78 to $428.19 | Robinhood and Barchart showed UNH around this area on July 8, 2026. Market cap math used $427.78. |
| Immediate support | $413 to $418 | This area brackets the 20-day moving average zone cited by Barchart and recent short-term trading support. |
| Moving-average support | $393 to $395 | Barchart cited the 50-day moving average near this area. A close below it would weaken the short-term recovery trend. |
| Major support | $338 to $339 | Barchart cited the 200-day moving average near this zone. A break would challenge the broader rebound thesis. |
| Near resistance | $428 to $434 | UNH was pressing against the recent high zone. Intellectia cited immediate resistance near $434.15. |
| Upper resistance | $450 to $470 | This is the bullish scenario extension zone if earnings and policy news continue to improve. |
| Moving averages | 50-day near $394, 200-day near $339 | Price above both moving averages keeps the trend constructive, but the spread also means chasing near resistance carries gap risk. |
| Momentum | 14-day RSI near 62.84 | Momentum is positive but not extreme. A move above $434 with volume would matter more than the RSI reading alone. |
| Volume | 50-day average near 6.8 million shares | Breakouts above the recent high zone should be judged against this volume reference and the next earnings catalyst. |
| Volatility | Watch July 16, 2026 earnings | Q2 results, medical care ratio, Medicare Advantage commentary, Optum margins, and legal disclosures are likely volatility drivers. |
| Invalidation | Close below $393, then below $338 | A sustained break below the 50-day average weakens the tactical setup. A break below the 200-day average would challenge the larger recovery read. |
UNH AI trading strategy
The UNH AI trading strategy below is a rules-based research framework, not personal advice. It combines chart confirmation with medical cost trend, Medicare Advantage repricing, Optum execution, cash flow, debt, dividend coverage, and regulatory risk.
Watch for UNH to hold above the $413 to $418 area and break above $428 to $434 with volume above the 50-day reference. Confirm that Q2 commentary supports the Q1 recovery and the 2026 adjusted EPS guide above $18.25.
A failed breakout followed by a close below the $393 to $395 50-day moving-average zone should reduce trend confidence, especially if medical cost or legal commentary worsens.
If UNH pulls back toward the 50-day or 200-day moving average without a permanent earnings reset, compare the lower price with normalized EPS, medical care ratio trends, Optum Health margins, free cash flow conversion, and debt-to-capital progress.
Do not treat a lower price as automatically attractive if Medicare Advantage pricing, DOJ exposure, CMS scrutiny, or Optum Health economics deteriorate.
Track Q2 2026 results, medical care ratio, UnitedHealthcare membership, Medicare Advantage attrition, Optum Health value-based care margins, Optum Rx policy risk, legal updates, operating cash flow, debt-to-capital, dividends, and buybacks.
Position sizing should reflect that UNH is a regulated recovery story with headline risk, not a guaranteed defensive stock.
Investment research summary
Customers pay UnitedHealth to organize access to care, pool insurance risk, manage pharmacy and medical costs, process claims, provide care delivery infrastructure, and simplify health care administration across employers, individuals, governments, and providers.
The moat comes from national scale, local provider networks, claims and pharmacy data, Optum services, UnitedHealthcare distribution, regulatory know-how, and deep relationships with employers and government programs. The moat narrows when pricing fails to keep up with utilization or when regulation limits economics.
The thesis fails if medical costs outrun repricing, Medicare Advantage economics reset structurally lower, Optum Health cannot fix value-based care losses, legal or compliance costs rise, PBM reform hurts Optum Rx, or public and political pressure reduces the allowed return on scale.
Stephen Hemsley returned as CEO after the 2025 disruption. The management test is no longer just growth. It is credibility, operating discipline, compliance, member trust, capital allocation, and whether AI and process investments produce measurable cost and service gains.
UnitedHealth sits inside long-term demand for health benefits, aging demographics, value-based care, pharmacy management, and health data infrastructure. The offset is that U.S. health care affordability keeps the sector under constant policy, legal, and political review.
At $427.78, UNH is not priced for collapse, even though trailing EPS still reflects the 2025 reset. Margin of safety improves only if adjusted EPS recovery converts into cleaner GAAP earnings, cash flow, lower leverage, and fewer legal or policy surprises.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| UNH quote reference | $427.78 on July 8, 2026 | Robinhood UNH quote | July 8, 2026 |
| Market capitalization verification | $388.49 billion reported and $388.49 billion calculated from $427.78 x 908.144404 million shares | Pineify financial_rigor.py and UnitedHealth Q1 2026 Form 10-Q | July 8, 2026 |
| Shares outstanding | 908,144,404 shares as of April 30, 2026 | UnitedHealth Q1 2026 Form 10-Q | July 8, 2026 |
| FY2025 revenue | $447.567 billion in the 2025 Form 10-K, cross-checked against the FY2025 release and Macrotrends | UnitedHealth 2025 Form 10-K | July 8, 2026 |
| FY2025 net earnings | $12.807 billion attributable to UnitedHealth Group common shareholders, with third-party total net earnings checks near $12.1 billion | UnitedHealth 2025 Form 10-K and Macrotrends | July 8, 2026 |
| Q1 2026 revenue and operating earnings | $111.7 billion revenue and $9.0 billion earnings from operations | UnitedHealth Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 adjusted EPS outlook | Full-year 2026 adjusted net earnings greater than $18.25 per share | UnitedHealth Q1 2026 earnings release | July 8, 2026 |
| Medical care ratio | 83.9% in Q1 2026, down 90 basis points year over year | UnitedHealth Q1 2026 earnings release | July 8, 2026 |
| Cash and short-term investments | MRQ checks near $31.2 billion, versus $28.121 billion at December 31, 2025 | StockAnalysis balance sheet and UnitedHealth FY2025 release | July 8, 2026 |
| Total debt | About $77.9 billion total debt in MRQ third-party balance sheet checks | Simply Wall St balance sheet health | July 8, 2026 |
| Technical moving averages | Barchart 50-day near $393 to $395, 200-day near $338 to $339, RSI near 62.84 | Barchart UNH technical analysis | July 8, 2026 |
| Q2 2026 earnings date | Scheduled for July 16, 2026 | UnitedHealth investor relations | July 8, 2026 |
This UNH AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if earnings, rates, regulation, litigation, medical costs, liquidity, or market sentiment change.
